Allergan, parent company of Juvéderm Volbella XC, received FDA approval for the use of the product in perioral lines and for augmentation of the lips in adults age 21 and older.
In clinical trials, Juvéderm Volbella XC showed an ability to soften the appearance of lines around the mouth and effectively increase lip fullness in a majority of subjects.
“Many of my patients are very bothered by the lines that can appear around the lips, known as perioral rhytids,” says David E. Bank, MD, clinical trial investigator and founder of The Center for Dermatology, Cosmetic & Laser Surgery, in a media release from Allergan.
“Additionally, when seeking lip augmentation, patients want a smooth result that’s not drastic. Juvéderm Volbella XC adds fullness to the lips and softens the appearance of the lines around the lips. With Juvéderm Volbella XC, I am able to subtly enhance my patients’ pout,” he adds.
Juvéderm Volbella XC is customized with a lower HA concentration (15 mg/mL) and provides the long-lasting results expected from the Juvéderm collection of fillers, according to the release. Juvéderm Volbella XC is the latest addition to Allergen’s Juvéderm portfolio. Juvéderm Volbella XC first received approval in Europe in 2011. Allergan distributes Juvéderm Volbella XC in 70 countries, including markets in Latin America, Europe, Middle East, Asia Pacific and Canada.
[Source(s): Allergan, PR Newswire]